Robeco Institutional Asset Management B.V. Has $87.08 Million Stock Position in Incyte Co. (NASDAQ:INCY)

Robeco Institutional Asset Management B.V. lessened its position in shares of Incyte Co. (NASDAQ:INCY) by 0.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,260,787 shares of the biopharmaceutical company’s stock after selling 5,179 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Incyte were worth $87,083,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of INCY. Public Sector Pension Investment Board raised its position in Incyte by 71.5% in the 2nd quarter. Public Sector Pension Investment Board now owns 6,322 shares of the biopharmaceutical company’s stock valued at $383,000 after buying an additional 2,636 shares during the last quarter. Creative Planning raised its holdings in shares of Incyte by 13.4% in the second quarter. Creative Planning now owns 21,059 shares of the biopharmaceutical company’s stock valued at $1,277,000 after purchasing an additional 2,496 shares during the last quarter. NewEdge Advisors LLC lifted its position in shares of Incyte by 23.9% in the second quarter. NewEdge Advisors LLC now owns 23,087 shares of the biopharmaceutical company’s stock worth $1,400,000 after purchasing an additional 4,456 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in Incyte by 204.6% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 9,350 shares of the biopharmaceutical company’s stock worth $567,000 after purchasing an additional 6,280 shares during the last quarter. Finally, EP Wealth Advisors LLC grew its position in Incyte by 9.1% in the second quarter. EP Wealth Advisors LLC now owns 3,961 shares of the biopharmaceutical company’s stock valued at $240,000 after purchasing an additional 332 shares in the last quarter. Institutional investors and hedge funds own 96.97% of the company’s stock.

Insider Buying and Selling at Incyte

In other Incyte news, EVP Steven H. Stein sold 12,352 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $72.69, for a total transaction of $897,866.88. Following the sale, the executive vice president now directly owns 66,967 shares in the company, valued at $4,867,831.23. This represents a 15.57 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Thomas Tray sold 650 shares of Incyte stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $69.31, for a total transaction of $45,051.50. Following the completion of the transaction, the insider now directly owns 23,312 shares in the company, valued at $1,615,754.72. This trade represents a 2.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 23,375 shares of company stock valued at $1,737,578 in the last quarter. Company insiders own 17.60% of the company’s stock.

Incyte Stock Performance

NASDAQ:INCY opened at $73.72 on Thursday. The company has a current ratio of 1.87, a quick ratio of 1.82 and a debt-to-equity ratio of 0.01. The stock has a 50 day simple moving average of $71.66 and a 200 day simple moving average of $68.68. Incyte Co. has a 1-year low of $50.35 and a 1-year high of $83.95. The stock has a market cap of $14.20 billion, a P/E ratio of 526.61, a PEG ratio of 0.53 and a beta of 0.71.

Incyte (NASDAQ:INCY) last announced its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.19 by ($0.12). Incyte had a net margin of 0.80% and a negative return on equity of 0.63%. The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.08 billion. During the same period in the previous year, the firm posted $0.91 EPS. The company’s revenue was up 23.8% compared to the same quarter last year. Research analysts anticipate that Incyte Co. will post 0.39 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on INCY shares. Morgan Stanley boosted their price target on shares of Incyte from $64.00 to $69.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 30th. Bank of America raised Incyte from a “neutral” rating to a “buy” rating and increased their price target for the company from $68.00 to $90.00 in a research report on Tuesday, October 29th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Incyte in a research report on Friday, January 10th. Citigroup upped their price objective on Incyte from $92.00 to $97.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Finally, Wells Fargo & Company raised their target price on shares of Incyte from $68.00 to $70.00 and gave the company an “equal weight” rating in a research note on Thursday, December 19th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $75.71.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.